Liminatus Pharma received a delisting notice from Nasdaq due to failure to meet minimum market value requirements for its listed securities and publicly held shares. The company was given until May 18, 2026, to regain compliance but did not meet the criteria. Nasdaq will suspend trading and delist Liminatus' securities on May 29, 2026, unless the company successfully appeals the decision. Liminatus intends to request an appeal, which will delay any suspension or delisting pending the hearing outcome.
Audiencerate Ltd has named Riccardo Fabbri as its new Chief Technology Officer, marking the start of an AI-driven expansion phase for its platforms serving Italian SMEs and global media agencies. Fabbri, with over 20 years of experience in software a...
Biogen and Denali announced that their Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson's disease did not meet its primary or secondary endpoints, showing no slowing of disease progression compared to placebo. Despite good safety and ...
Samba TV has introduced Project Gravity, an independent data onboarding and activation platform that integrates advertisers' first-party data with over 40 leading advertising platforms like Google DV360, Meta, and TikTok. Designed for the agentic era...
Biogen and Denali announced that their Phase 2b LUMA study of BIIB122, a drug targeting early-stage Parkinson's disease, did not meet its primary or secondary endpoints, showing no slowing of disease progression compared to placebo. Despite good safe...
IMAX is reportedly exploring a potential sale, approaching entertainment firms, though talks are early and may not lead to a deal. The company has seen strong growth, with its premium large-format theaters increasing their share of U.S. and Canadian ...
